Latest news with #EURONEXT
Business Wire
4 hours ago
- Business
- Business Wire
Wolters Kluwer Hosts 'Storm Chasing' Session on Regulatory Complexity at 2025 ABA Risk & Compliance Conference
INDIANAPOLIS--(BUSINESS WIRE)--Regulatory compliance experts with Wolters Kluwer Compliance Solutions will present practical insights for financial institutions on managing challenges amid the current "regulatory storm" of crypto expansion, varying state-level requirements and federal deregulation initiatives. The insights will be shared during a breakfast panel session at the American Bankers Association's 2025 Risk and Compliance Conference. " Storm Chasing: Crypto Cyclones, State-Level Squalls, and the Deregulation Downpour," will take place from 7:30 – 8:15 AM ET on Wednesday, June 11, 2025, at the Indiana Convention Center in Indianapolis. "The 2025 regulatory landscape presents unprecedented complexity: while federal deregulation gains momentum, state-level enforcement intensifies, creating a patchwork of compliance requirements," says Thomas Grundy, Wolters Kluwer. Participants in this panel discussion from Wolters Kluwer Compliance Solutions include Thomas Grundy, Director, U.S. Advisory Services; Kris Stewart, Senior Director, Product Management; and Elaine Duffus, Senior Specialized Consultant, Compliance Program Management. "The 2025 regulatory landscape presents unprecedented complexity: while federal deregulation gains momentum, state-level enforcement intensifies, creating a patchwork of compliance requirements," explains Thomas Grundy. "As banks remain in a collective holding pattern, our session provides the strategic foresight needed to prepare for whatever lies ahead." Wolters Kluwer will also host an exclusive rooftop reception at Cannonball Lounge on Tuesday, June 10 from 6:30 PM – 8:30 PM. The event will gather banking leaders to explore ongoing compliance challenges and how Wolters Kluwer's AI-first technology solutions can help address them. Attendees will get a first look at Compliance Intelligence, a new solution that leverages trusted expertise and advanced AI to help financial institutions navigate regulatory change and obligation management with confidence. Conference attendees can access additional Wolters Kluwer resources and schedule meetings with compliance experts through the company's dedicated ABA event hub. Wolters Kluwer Compliance Solutions is a market leader and trusted provider of risk management and regulatory compliance solutions and services to U.S. banks, credit unions, insurers and securities firms. The business, which sits within Wolters Kluwer's Financial & Corporate Compliance (FCC) division, helps these financial institutions efficiently manage risk and regulatory compliance obligations, and gain the insights needed to focus on better serving their customers and growing their business. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, corporate performance, and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit and follow us on LinkedIn, Facebook, YouTube, and Instagram.
Yahoo
9 hours ago
- Business
- Yahoo
Share Buyback Transaction Details May 29 – June 4, 2025
PRESS RELEASE Share Buyback Transaction Details May 29 – June 4, 2025 Alphen aan den Rijn – June 5, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 225,452 of its own ordinary shares in the period from May 29, 2025, up to and including June 4, 2025, for €35.2 million and at an average share price of €155.93. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 2,750,306 427.5 155.43 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.06.05 Share Buyback Transactions May 29 - Jun 4 2025Sign in to access your portfolio
Business Wire
3 days ago
- Business
- Business Wire
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg ® (MaaT013) in Acute Graft-versus-Host Disease
LYON, France--(BUSINESS WIRE)--Regulatory News: 'Submitting our MAA to the EMA marks a major regulatory milestone for MaaT Pharma and a meaningful advancement for patients with refractory aGvHD—a life-threatening complication of stem cell transplantation with no approved therapies" Share MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under the registered brand name of Xervyteg ®. If approved, the Marketing Authorization would establish Xervyteg ® as the first microbiota therapeutic approved by the EMA, and the first one globally for a hematology indication. Xervyteg ® would also be the first approved therapy for the treatment of acute Graft-versus-Host Disease including gastro-intestinal involvement (GI-aGvHD) following 2 prior lines of systemic therapy. 'Submitting our MAA to the EMA marks a major regulatory milestone for MaaT Pharma and a meaningful advancement for patients with refractory aGvHD—a life-threatening complication of stem cell transplantation with no approved therapies,' said Hervé Affagard, Co-founder and CEO of MaaT Pharma. 'We are now closer to providing a much-needed treatment option and remain deeply committed to advancing immunomodulating microbiota technologies in hemato-oncology, where new solutions are urgently needed.' While advancing toward the commercialization of Xervyteg ® (if approved) in Europe, MaaT Pharma is also actively exploring strategic partnerships to ensure broad access in timely fashion. The Company has active discussions with experienced partners who share its mission of delivering meaningful advancements to patients. In parallel to the MAA submission, MaaT Pharma continues to provide access to Xervyteg ® in Europe and the U.S. through its Early Access Program (EAP) 1 for patients with aGvHD and other indications. In 2024, physician demand for Xervyteg ® under the EAP (n=107) increased by 75% compared to 2023, driven by growing adoption across Europe and in the U.S. In France where the EAP first started, MaaT Pharma has captured 25% of the addressable market on a yearly basis in 2024. Overall, this position reflects the increasing recognition of Xervyteg ® as a valuable treatment option for GI-aGvHD patients. aGvHD is the most severe complication of allogeneic stem cell transplantation, a standard-of-care treatment with curative intent offered to patients with blood cancers and some non-malignant hematological conditions. aGvHD refractoriness to current treatments is frequently encountered and severely impacts prognosis. In particular, patients with aGvHD failing both steroid and ruxolitinib typically exhibit a dismal prognosis, with a median survival of 28 days and 85% mortality at one year (Abedin et al 2021). Currently, no therapy is approved for third-line aGvHD, underscoring the urgent need for innovative therapies capable of improving survival and quality of life. The MAA is supported by positive results from the Pivotal ARES study, a single-arm, open-label, multicenter European study evaluating the efficacy and safety of Xervyteg ® in GI-aGvHD as third-line therapy in 66 patients. Notably, the study met its primary endpoint, achieving a gastrointestinal overall response rate (GI-ORR) of 62% at Day 28, significantly exceeding the expected 38% response rate, and an overall response rate across all organs of 64% at Day 28. Among responding patients at Day 28, the majority exhibited full resolution of GvHD clinical manifestations (i.e., complete response), an important finding predictive of durable control of aGvHD clinical manifestations over time. The 12-month probability of survival was 54% (vs 15% Abedin et al, 2021). Importantly, patients who exhibited gastrointestinal response at Day 28 had a significantly better probability of survival than non-responders (67% vs 28% respectively, p <0.0001), indicating that Xervyteg ® -mediated aGvHD control is associated with a remarkable survival benefit. Additional secondary endpoints, including overall survival, will become available in late H2 2025. The Company also integrated supporting safety and efficacy data from 186 aGvHD patients 2 treated under its ongoing EAP, which aligns with the positive topline results of the ARES trial and further supports Xervyteg ® 's strong efficacy and favorable safety profile in aGvHD. The safety and tolerability of Xervyteg ® has been monitored by an independent Data Safety Monitoring Board (DSMB). In March 2025, the DSMB reviewed the overall safety of the trial (after all patients completed Day 28 visit or were discontinued earlier) and confirmed that 'given the remarkable efficacy results, the study results show an acceptable safety profile and a favourable benefit /risk ratio'. The DSMB members will continue to review safety on an ongoing basis until the 1-year follow-up. The EMA will review the application under the centralized marketing authorization procedure and potentially a marketing authorization could be granted in H2 2026. This centralized procedure means that a single marketing authorization application can be submitted to the EU, and if granted by the European Commission, the authorization is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway. About acute Graft-versus-Host Disease Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient's organs, causing inflammation of the skin, liver and/or gastro-intestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered Steroid Resistant (SR) and other agents can be administered. Currently the only agent approved for treating SR aGvHD after failure of steroid treatment is ruxolitinib, which is currently approved for this indication in USA and has received approval from the European Medical Agency's Committee for Human Medicinal Products (CHMP) on March 25, 2022. About Xervyteg ® (MaaT013) MaaT Pharma's Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. Xervyteg ® (MaaT013) is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy TM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore TM (a group of bacterial species known to produce anti-inflammatory metabolites). Xervyteg ® (MaaT013) aims to restore the symbiotic relationship between the patient's functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. Xervyteg ® (MaaT013) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. presented at the EHA Annual Congress 2 The cutoff date was October 3, 2024
Business Upturn
6 days ago
- Health
- Business Upturn
Wolters Kluwer Launches Lippincott Nursing Advisory Board to Elevate Clinical Excellence in India
By Business Wire Published on May 30, 2025, 15:28 IST New Delhi, Delhi, India: Wolters Kluwer is proud to announce the launch of the Lippincott Nursing Advisory Board, a groundbreaking initiative committed to advancing nursing excellence, standardizing care, and enhancing patient outcomes through evidence-based knowledge and clinical decision support. Launched today at ANEICON, the largest nursing conference in India, this Advisory Board is driven by a commitment to continuous professional development and the 'Make it Better' mission of Wolters Kluwer (Lippincott Solutions). The Lippincott Nursing Advisory Board brings together a distinguished panel of nursing leaders and experts from both academic and clinical practice settings. Their collective expertise will guide the evolution of Lippincott Solutions, ensuring that the tools and resources offered are aligned with the real-world challenges and aspirations of the nursing community. The board will play a pivotal role in advising on clinical and professional trends, offering insights into leadership challenges such as compliance, onboarding, and education, providing feedback on product development and messaging strategies, identifying and addressing knowledge and technology gaps, sharing perspectives on health economics, and encouraging data and information management for predictive intelligence and forecasts. Commenting on this development, Ruchi Tushir, VP & General Manager, GGM India, at Wolters Kluwer, expressed,'We are incredibly excited about the launch of the Lippincott Nursing Advisory Board. This initiative represents a significant step forward in supporting the nursing community and enhancing patient care through collaboration and innovation. The insights and expertise of our Nursing Advisory Board will be invaluable in developing solutions that address the evolving needs of the healthcare industry.' This initiative is rooted in Wolters Kluwer's mission to 'Make it Better' by fostering collaboration, innovation, and advocacy within the nursing profession. By creating a platform for dialogue and shared learning, the Lippincott Nursing Advisory Board aims to elevate the standards of care and support the professional growth of nurses across India. The launch of the board is timed to coincide withANEICON, one of the country's most prominent nursing conferences, underscoring the importance of this endeavor within the broader healthcare landscape. Providing clinical, evidence-based content trusted across India Lippincott Solutions is a trusted partner for healthcare organizations, providing evidence-based tools and resources to support clinical decision-making, enhance patient care, and advance professional development. With a commitment to excellence and innovation, AI- powered Lippincott Solutions empowers healthcare professionals to deliver the highest quality care. Learn more about Wolters Kluwer: About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Business Wire is an American company that disseminates full-text press releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other audiences.
Business Wire
6 days ago
- Business
- Business Wire
Wolters Kluwer Launches Lippincott Nursing Advisory Board to Elevate Clinical Excellence in India
NEW DELHI--(BUSINESS WIRE)-- Wolters Kluwer is proud to announce the launch of the Lippincott Nursing Advisory Board, a groundbreaking initiative committed to advancing nursing excellence, standardizing care, and enhancing patient outcomes through evidence-based knowledge and clinical decision support. Launched today at ANEICON, the largest nursing conference in India, this Advisory Board is driven by a commitment to continuous professional development and the 'Make it Better' mission of Wolters Kluwer (Lippincott Solutions). The Lippincott Nursing Advisory Board brings together a distinguished panel of nursing leaders and experts from both academic and clinical practice settings. Their collective expertise will guide the evolution of Lippincott Solutions, ensuring that the tools and resources offered are aligned with the real-world challenges and aspirations of the nursing community. The board will play a pivotal role in advising on clinical and professional trends, offering insights into leadership challenges such as compliance, onboarding, and education, providing feedback on product development and messaging strategies, identifying and addressing knowledge and technology gaps, sharing perspectives on health economics, and encouraging data and information management for predictive intelligence and forecasts. Commenting on this development, Ruchi Tushir, VP & General Manager, GGM India, at Wolters Kluwer, expressed, 'We are incredibly excited about the launch of the Lippincott Nursing Advisory Board. This initiative represents a significant step forward in supporting the nursing community and enhancing patient care through collaboration and innovation. The insights and expertise of our Nursing Advisory Board will be invaluable in developing solutions that address the evolving needs of the healthcare industry.' This initiative is rooted in Wolters Kluwer's mission to 'Make it Better' by fostering collaboration, innovation, and advocacy within the nursing profession. By creating a platform for dialogue and shared learning, the Lippincott Nursing Advisory Board aims to elevate the standards of care and support the professional growth of nurses across India. The launch of the board is timed to coincide with ANEICON, one of the country's most prominent nursing conferences, underscoring the importance of this endeavor within the broader healthcare landscape. Providing clinical, evidence-based content trusted across India Lippincott Solutions is a trusted partner for healthcare organizations, providing evidence-based tools and resources to support clinical decision-making, enhance patient care, and advance professional development. With a commitment to excellence and innovation, AI- powered Lippincott Solutions empowers healthcare professionals to deliver the highest quality care. Learn more about Wolters Kluwer: About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
